GSH (L-Glutathione reduced) Clinical Trials

Size	Price	Qty
100mg	USD 147
500mg	USD 297

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate the therapeutic applications of reduced L-glutathione across diverse indications, including diabetes mellitus, ischemia-reperfusion injury, dermatological conditions, autistic disorder, and viral infections such as COVID-19. Sponsored predominantly by university medical centers and academic research institutes globally, these studies assess physiological parameters ranging from liver transplantation injury to glycemic and inflammatory profiles. Recruitment statuses vary from active and recruiting to completed, with select studies withdrawn or terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07304440	RECRUITING	Autism Spectrum Disorder; Autism; ASD; Autism Spectrum Disorder (ASD)	Adia Med of Winter Park LLC	2026-05-01	PHASE1; PHASE2
NCT07572890	RECRUITING	Chronic Kidney Disease; Kidney Disease; Kidney Disease, Chronic; Chronic Kidney Disease (CKD); CKD	Adia Med of Winter Park LLC	2026-05-18	PHASE1
NCT02971046	ACTIVE_NOT_RECRUITING	Healthy	The Hospital for Sick Children	2020-10-01
NCT05266417	RECRUITING	Parkinson Disease	Gateway Institute for Brain Research	2022-02-07	PHASE2
NCT07064005	RECRUITING	Parkinsons Disease (PD)	Pravat Mandal	2026-03-23	PHASE1
NCT06620523	RECRUITING	Renal Failure; Coronary Artery Disease; Surgery; Surgery-Complications	George Washington University	2024-07-18	PHASE2
NCT06922669	RECRUITING	Drug Induced Liver Injury	General Hospital of Shenyang Military Region	2025-06-24
NCT07448415	NOT_YET_RECRUITING	Melasma	Assiut University	2026-02	PHASE2; PHASE3
NCT06957808	RECRUITING	Schizophrenia Disorders	King's College London	2025-01-10
NCT07595705	RECRUITING	Gingival Pigmentation; Depigmentation; Vitamin C; Glutathione	Cairo University	2025-08-01	PHASE2
NCT06896422	RECRUITING	Non-Small Cell Lung Cancer; Chemotherapy; PD1 Antibody; Glutathione	The First Affiliated Hospital of Zhengzhou University	2025-06-01	PHASE1
NCT07622316	RECRUITING	Autism Spectrum Disorder; Autism; ASD; Autism Spectrum Disorder (ASD)	Greater Atlanta Integrative Pediatrics	2026-06-01	PHASE1
NCT07690124	NOT_YET_RECRUITING	Performance Recovery; Exercise-induced Inflammation; Exercise-induced Oxidative Stress	University of Thessaly	2026-09-01
NCT07379216	RECRUITING	Skin Condition; Anti-Oxidative Stress	TCI Co., Ltd.	2026-01-24
NCT04740580	RECRUITING	Alzheimer Disease	Baylor College of Medicine	2022-02-15	EARLY_PHASE1
NCT07162623	COMPLETED	Hyperpigmentation	NovoBliss Research Pvt Ltd	2025-09-02
NCT05241262	RECRUITING	Mitochondrial Disease	Michio Hirano, MD	2023-07-06	PHASE1
NCT07202156	RECRUITING	Melasma (Facial Melasma)	The First Affiliated Hospital with Nanjing Medical University	2024-10-20
NCT07302828	COMPLETED	Vitamin C; Glutathione	TCI Co., Ltd.	2025-12-15
NCT07748507	COMPLETED	Gingiival Hyperpigmentation	Krishnadevaraya College of Dental Sciences & Hospital	2025-06-25
NCT07263841	ACTIVE_NOT_RECRUITING	Post Burn Facial Hyperpigmentation	King Edward Medical University	2025-06-01	PHASE2
NCT07221955	NOT_YET_RECRUITING	Effects of Qualia Glutathione+ on Blood Glutathione Levels; Glutathione	Qualia Life Sciences	2025-12-02
NCT07344688	COMPLETED	Healhty	Universitas Padjadjaran	2025-08-22
NCT07724067	COMPLETED	MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)	University of Bari	2024-05-01
NCT05371288	WITHDRAWN	COVID-19	University of California, Irvine	2025-06	EARLY_PHASE1
NCT06345950	COMPLETED	Bioavailability Heathy Volunteers; Safety	Factors Group of Nutritional Companies Inc.	2022-06-21
NCT03493178	ACTIVE_NOT_RECRUITING	Mild Cognitive Impairment	Baylor College of Medicine	2018-04-19	EARLY_PHASE1
NCT05604586	COMPLETED	Skeletal Muscle Performance; Gene Polymorphisms	Poznan University of Life Sciences	2022-05-01
NCT04020224	WITHDRAWN	Safety Issues	Swiss Transfusion SRC	2024-01
NCT06205030	Not yet recruiting	Diabetes Mellitus Type 2\|Insulin Resistance	Kerman Medical University\|Afzalipour Hospital	2024-06-14	Phase 4
NCT06313164	COMPLETED	Type 2 Diabetes	S.LAB (SOLOWAYS)	2023-06-20
NCT05954052	TERMINATED	Autism Spectrum Disorder	University of Chicago	2019-07-01	PHASE4
NCT05693948	COMPLETED	Healthy	USMARI Research & Innovation Centre	2022-09-01
NCT06419712	COMPLETED	Post-COVID19 Condition	Escuela Militar de Graduados de Sanidad, SEDENA	2022-11-25
NCT03166371	WITHDRAWN	Malnutrition	Emory University	2022-02
NCT02505477	COMPLETED	Schizophrenia; Cognitive Deficits; Schizophrenia; Negative Type	University of California, Los Angeles	2017-02-06	PHASE4
NCT05511402	UNKNOWN	Parkinson Disease	Saglik Bilimleri Universitesi	2022-08-25
NCT05926245	COMPLETED	Glutathione-cyclodextrin Complex Absorption	Western University of Health Sciences	2022-07-11	PHASE1
NCT02827747	WITHDRAWN	Keratoconus	University of Miami	2021-08-01	PHASE2
NCT04015557	SUSPENDED	CBS Deficiency	Hospital de Clinicas de Porto Alegre	2022-02-11	PHASE1; PHASE2
NCT04672447	COMPLETED	Menopause; Cardiovascular Risk Factor	Texas Tech University	2020-07-01
NCT03596125	TERMINATED	Preterm Delivery	Nantes University Hospital	2018-11-05	PHASE2; PHASE3
NCT04816487	UNKNOWN	Discoloration, Tooth	Cairo University	2021-05-01
NCT04386187	COMPLETED	Type 2 Diabetes	University of California, San Diego	2020-07-28
NCT01967667	COMPLETED	Schizophrenia	University of Maryland, Baltimore	2014-04
NCT04389788	COMPLETED	Periorbital Hypermelanosis	Sohag University	2020-02-12
NCT03725241	COMPLETED	Healthy	University of North Texas, Denton, TX	2018-10-29
NCT04175873	COMPLETED	Infertility; Anesthesia; Oxidative Stress; Pain, Postoperative	Kahramanmaras Sutcu Imam University	2019-11-25
NCT03486054	WITHDRAWN	Anemia	Swiss Transfusion SRC	2019-06
NCT02584283	COMPLETED	Liver Failure; End Stage Liver Disease; Biliary Tract Diseases	Robert J. Porte	2016-01	PHASE3
NCT02848417	UNKNOWN	Gulf War Syndrome	South Florida Veterans Affairs Foundation for Research and Education	2016-04	PHASE1; PHASE2
NCT01870193	COMPLETED	Aging	Rajagopal V Sekhar	2013-04-23	EARLY_PHASE1
NCT02757833	WITHDRAWN	Female, Late Life Depression	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	2019-02-15	PHASE1
NCT02251041	COMPLETED	Reperfusion Injury	Universitaire Ziekenhuizen KU Leuven	2014-09	PHASE2
NCT03020719	COMPLETED	Cystic Fibrosis	University of Minnesota	2017-06-14	PHASE2
NCT02348775	COMPLETED	HIV Infection; Erythrocyte Glutathione Deficiency	Baylor College of Medicine	2014-11	PHASE1
NCT04105504	COMPLETED	Glutathione; Skin Whitening	Dr Irma Bernadette S Sitohang	2018-04-08	PHASE1
NCT03374150	UNKNOWN	Low-Calorie Diet; Diet, High-Protein; Obesity; Pituitary; Weight Cycling	Indonesia University	2017-05-26
NCT02948673	COMPLETED	Type 2 Diabetes; Oxidative Stress; Mitochondrial Reactive Oxygen Species Production	University of Copenhagen	2016-05
NCT02794389	COMPLETED	Anorexia Nervosa; Compulsive Behavior	University of Oxford	2016-03
NCT02321579	UNKNOWN	Liver Cirrhosis; Liver Cancer	Taichung Veterans General Hospital	2014-12
NCT02662816	COMPLETED	Assay Muscle; Liver Glutathione in Healthy Human	University Hospital, Clermont-Ferrand	2016-06
NCT02438956	COMPLETED	Improvement in Immune Cell Function in Elderly Humans	University of Florida	2015-10
NCT02424708	COMPLETED	Parkinson's Disease	Bastyr University	2015-04	PHASE2
NCT03121222	COMPLETED	Glutathione Metabolism Anemias	Aristotle University Of Thessaloniki	2015-11-01	PHASE2
NCT01398748	COMPLETED	Parkinson's Disease (PD)	Bastyr University	2012-07	PHASE1
NCT00069134	COMPLETED	Protein-energy Malnutrition; Kwashiorkor; Marasmus	Baylor College of Medicine	2003-06
NCT00287365	COMPLETED	Mild Asthma	University of North Carolina, Chapel Hill	2006-01
NCT02316925	WITHDRAWN	Improvement in Immune Cell Function in Elderly Humans	University of Florida	2015-05
NCT02278822	COMPLETED	Healthy	Milton S. Hershey Medical Center	2014-11
NCT02324426	COMPLETED	Parkinson's Disease	University of Washington	2014-12	PHASE1
NCT02310971	WITHDRAWN	Pancreatic Carcinoma Stage I; Pancreatic Carcinoma Stage II	Prima BioMed Ltd	2015-02	PHASE2
NCT01521143	TERMINATED	Epithelial Ovarian Cancer	Prima BioMed Ltd	2012-01	PHASE2
NCT01265563	COMPLETED	Diabetic Nephropathy; Proteinuria; Oxidative Stress	VA Office of Research and Development	2011-01	PHASE2
NCT02125045	COMPLETED	Health Subjects With Cardiovascular Risk Factors	Niguarda Hospital	2014-02	PHASE3
NCT01402570	COMPLETED	Post-polio Syndrome; Physical Activity; Depression; Pain; Sleep Disorders	University of Michigan	2011-08
NCT01071486	WITHDRAWN	Busulfan Pharmacokinetic Analysis; GST Genetic Polymorphism	Rambam Health Care Campus	2009-08	PHASE4
NCT00889538	COMPLETED	Autism; Severe Behavior Disorder	University of Louisville	2009-04
NCT02311907	COMPLETED	Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer	Alliance for Clinical Trials in Oncology	2009-12	PHASE3
NCT01550432	COMPLETED	Obesity; Hyperlipidemia; Insulin Resistance; Hypertension	Stanford University	2011-06
NCT01450267	UNKNOWN	Cystic Fibrosis	Serafino A. Marsico	2010-06	PHASE3
NCT01403506	UNKNOWN	Disorder Related to Renal Transplantation	Shahid Beheshti University of Medical Sciences	2011-04	PHASE3
NCT02029521	COMPLETED	Cystic Fibrosis	Clark Bishop	2011-03
NCT01044277	COMPLETED	Healthy Adults	Milton S. Hershey Medical Center	2010-02
NCT01355198	COMPLETED	HIV Infection; Erythrocyte Glutathione Deficiency	Baylor College of Medicine	2010-08	PHASE1
NCT01251315	COMPLETED	Oxidative Stress	Charles Drew University of Medicine and Science	2010-12	PHASE1
NCT00266331	COMPLETED	Breast Cancer	Nathalie Johnson	2004-10	PHASE2
NCT00858273	COMPLETED	Diabetes Mellitus, Type 1	Nemours Children's Clinic	2008-03
NCT01142024	COMPLETED	Nephropathy; Oxidative Stress	Huashan Hospital	2010-03
NCT00254176	UNKNOWN	Sepsis; Bronchopulmonary Dysplasia; Necrotizing Enterocolitis; Retinopathy of Prematurity; Systemic Inflammatory Response Syndrome	University of California, Los Angeles	2006-09	PHASE2; PHASE3
NCT00607061	TERMINATED	Low Birth Weight	Nantes University Hospital	2007-10
NCT00506688	COMPLETED	Cystic Fibrosis	Mukoviszidose Institut gGmbH	2007-07	PHASE2
NCT01016080	COMPLETED	Skin Whitening	Chulalongkorn University	2009-02	PHASE1
NCT00858897	COMPLETED	Diabetes Mellitus, Type 1	Nemours Children's Clinic	2007-06
NCT01116596	COMPLETED	Chronic Pain; Elderly	University Hospital, Clermont-Ferrand	2007-02	PHASE1
NCT00692315	COMPLETED	Autistic Disorder	Arkansas Children's Hospital Research Institute	2006-09
NCT01177319	COMPLETED	Parkinson's Disease	University of South Florida	2003-09	PHASE2
NCT00910442	COMPLETED	HIV Infection	UPECLIN HC FM Botucatu Unesp	2002-02	PHASE2
NCT01506765	COMPLETED	Schizophrenia	Centre Hospitalier Universitaire Vaudois	2003-08	PHASE1
NCT00227058	COMPLETED	Seasonal Allergic Rhinitis	University of Mississippi Medical Center	2005-01
NCT00127309	COMPLETED	Alcohol Drinking	Piyavate Hospital	2005-06
NCT00323583	UNKNOWN	Adenocarincoma of Pancreas; Stage III Pancreatic Cancer; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer	Seattle Cancer Treatment and Wellness Center	2006-05	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Check the GSH (L-Glutathione reduced) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an endogenous tripeptide antioxidant, reduced L-glutathione serves as a substrate for glutathione peroxidase and glutathione S-transferases, directly scavenging reactive oxygen species and conjugating electrophilic compounds to prevent intracellular lipid peroxidation and oxidative damage. By maintaining cellular redox homeostasis and preventing oxidative cell injury, this detoxifying mechanism directly supports clinical interventions aimed at reducing tissue damage in ischemia-reperfusion injury and improving metabolic outcomes in type 2 diabetes mellitus.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).